PL3527199T3 - Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację - Google Patents
Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalacjęInfo
- Publication number
- PL3527199T3 PL3527199T3 PL19167839.0T PL19167839T PL3527199T3 PL 3527199 T3 PL3527199 T3 PL 3527199T3 PL 19167839 T PL19167839 T PL 19167839T PL 3527199 T3 PL3527199 T3 PL 3527199T3
- Authority
- PL
- Poland
- Prior art keywords
- corticosteroid
- adrenergic
- inhalation
- beta
- administration
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152392 | 2012-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3527199T3 true PL3527199T3 (pl) | 2022-12-12 |
Family
ID=47715987
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19167775.6T PL3527196T3 (pl) | 2012-01-25 | 2013-01-23 | Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację |
| PL19167839.0T PL3527199T3 (pl) | 2012-01-25 | 2013-01-23 | Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację |
| PL13704372T PL2806855T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe, zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL19167835.8T PL3527198T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL18181331.2T PL3412277T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL19167829.1T PL3527197T3 (pl) | 2012-01-25 | 2013-01-23 | Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19167775.6T PL3527196T3 (pl) | 2012-01-25 | 2013-01-23 | Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13704372T PL2806855T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe, zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL19167835.8T PL3527198T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL18181331.2T PL3412277T3 (pl) | 2012-01-25 | 2013-01-23 | Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| PL19167829.1T PL3527197T3 (pl) | 2012-01-25 | 2013-01-23 | Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US10028964B2 (pl) |
| EP (7) | EP3527196B1 (pl) |
| JP (1) | JP6104282B2 (pl) |
| KR (3) | KR101895279B1 (pl) |
| CN (2) | CN104080444B (pl) |
| AR (1) | AR089805A1 (pl) |
| AU (1) | AU2013211656B2 (pl) |
| BR (1) | BR112014017481A8 (pl) |
| CA (1) | CA2862548C (pl) |
| CL (1) | CL2014001966A1 (pl) |
| CO (1) | CO7010836A2 (pl) |
| CY (1) | CY1120684T1 (pl) |
| DK (6) | DK3527199T3 (pl) |
| EA (2) | EA026267B1 (pl) |
| ES (6) | ES2929807T3 (pl) |
| FI (2) | FI3527198T3 (pl) |
| GE (1) | GEP201706767B (pl) |
| HR (6) | HRP20230147T1 (pl) |
| HU (6) | HUE040525T2 (pl) |
| IL (1) | IL233784A0 (pl) |
| LT (5) | LT3412277T (pl) |
| MA (1) | MA35859B1 (pl) |
| MX (2) | MX368199B (pl) |
| MY (1) | MY165888A (pl) |
| NZ (1) | NZ627837A (pl) |
| PE (1) | PE20141703A1 (pl) |
| PH (1) | PH12014501565B1 (pl) |
| PL (6) | PL3527196T3 (pl) |
| PT (6) | PT3527196T (pl) |
| RS (5) | RS63761B1 (pl) |
| SG (1) | SG11201404350PA (pl) |
| SI (3) | SI2806855T1 (pl) |
| TN (1) | TN2014000322A1 (pl) |
| TW (1) | TWI559940B (pl) |
| UA (1) | UA115543C2 (pl) |
| WO (1) | WO2013110632A1 (pl) |
| ZA (1) | ZA201405464B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3527199T3 (da) * | 2012-01-25 | 2022-10-24 | Chiesi Farm Spa | Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation |
| KR102275904B1 (ko) | 2013-07-11 | 2021-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
| UA118861C2 (uk) * | 2013-12-06 | 2019-03-25 | Оріон Корпорейшн | Спосіб отримання сухих порошкових композицій для інгаляцій |
| JP6919093B2 (ja) | 2014-10-08 | 2021-08-18 | ザンボン ソシエタ ペル アチオニ | 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物 |
| CN109789107B (zh) * | 2016-09-29 | 2021-12-03 | 广东东阳光药业有限公司 | 药物组合物 |
| EP3621590B1 (en) * | 2017-05-11 | 2021-09-01 | Chiesi Farmaceutici S.p.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| EP3687500A1 (en) | 2017-09-29 | 2020-08-05 | Crititech, Inc. | Glucocorticoid particles and their use |
| EP3833964B1 (en) | 2018-08-07 | 2023-07-26 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| JP7368065B2 (ja) | 2018-10-30 | 2023-10-24 | キエージィ ファーマチェウティチ エス．ペー．アー． | 人工呼吸器を装着している患者に薬物を投与するための装置 |
| KR102898819B1 (ko) | 2019-09-24 | 2025-12-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제를 위한 신규 담체 입자 |
| US20240033222A1 (en) | 2020-08-14 | 2024-02-01 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate |
| US20250050042A1 (en) * | 2021-12-21 | 2025-02-13 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| CA2347856C (en) * | 1998-11-13 | 2009-02-17 | Jagotec Ag | Dry powder for inhalation |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| PT1386630E (pt) | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| WO2010097188A1 (en) * | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| JP2012526726A (ja) * | 2009-05-15 | 2012-11-01 | 株式会社新日本科学 | 薬物動態が改善された鼻腔内用薬学的組成物 |
| GB0914240D0 (en) | 2009-08-14 | 2009-09-30 | Breath Ltd | Steroid solvates |
| RU2650175C2 (ru) * | 2009-10-02 | 2018-04-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтические аэрозольные препараты формотерола и беклометазона дипропионата |
| BR112012024059B1 (pt) * | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| DK2560611T3 (en) | 2010-04-21 | 2018-02-26 | Chiesi Farm Spa | Process for providing particles with reduced electrostatic charges |
| DK3527199T3 (da) * | 2012-01-25 | 2022-10-24 | Chiesi Farm Spa | Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation |
| KR102275904B1 (ko) * | 2013-07-11 | 2021-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
-
2013
- 2013-01-23 DK DK19167839.0T patent/DK3527199T3/da active
- 2013-01-23 EP EP19167775.6A patent/EP3527196B1/en active Active
- 2013-01-23 HR HRP20230147TT patent/HRP20230147T1/hr unknown
- 2013-01-23 LT LTEP18181331.2T patent/LT3412277T/lt unknown
- 2013-01-23 RS RS20221007A patent/RS63761B1/sr unknown
- 2013-01-23 PT PT191677756T patent/PT3527196T/pt unknown
- 2013-01-23 ES ES19167839T patent/ES2929807T3/es active Active
- 2013-01-23 SI SI201331186T patent/SI2806855T1/sl unknown
- 2013-01-23 MY MYPI2014002176A patent/MY165888A/en unknown
- 2013-01-23 ES ES19167829T patent/ES2929137T3/es active Active
- 2013-01-23 SI SI201332032T patent/SI3412277T1/sl unknown
- 2013-01-23 PT PT191678390T patent/PT3527199T/pt unknown
- 2013-01-23 HR HRP20221433TT patent/HRP20221433T1/hr unknown
- 2013-01-23 HR HRP20181550TT patent/HRP20181550T1/hr unknown
- 2013-01-23 SI SI201332092T patent/SI3527198T1/sl unknown
- 2013-01-23 WO PCT/EP2013/051187 patent/WO2013110632A1/en not_active Ceased
- 2013-01-23 EP EP18181331.2A patent/EP3412277B1/en active Active
- 2013-01-23 SG SG11201404350PA patent/SG11201404350PA/en unknown
- 2013-01-23 CN CN201380006645.XA patent/CN104080444B/zh active Active
- 2013-01-23 BR BR112014017481A patent/BR112014017481A8/pt not_active Application Discontinuation
- 2013-01-23 CN CN201610080909.1A patent/CN105726548B/zh active Active
- 2013-01-23 EP EP13704372.5A patent/EP2806855B1/en active Active
- 2013-01-23 HR HRP20221432TT patent/HRP20221432T1/hr unknown
- 2013-01-23 EP EP19167839.0A patent/EP3527199B1/en active Active
- 2013-01-23 KR KR1020177027831A patent/KR101895279B1/ko active Active
- 2013-01-23 PL PL19167775.6T patent/PL3527196T3/pl unknown
- 2013-01-23 AU AU2013211656A patent/AU2013211656B2/en active Active
- 2013-01-23 HU HUE13704372A patent/HUE040525T2/hu unknown
- 2013-01-23 DK DK18181331.2T patent/DK3412277T3/da active
- 2013-01-23 HU HUE19167829A patent/HUE060421T2/hu unknown
- 2013-01-23 HU HUE19167839A patent/HUE060705T2/hu unknown
- 2013-01-23 ES ES19167835T patent/ES2996893T3/es active Active
- 2013-01-23 EA EA201491281A patent/EA026267B1/ru unknown
- 2013-01-23 PT PT137043725T patent/PT2806855T/pt unknown
- 2013-01-23 US US14/417,484 patent/US10028964B2/en active Active
- 2013-01-23 LT LTEP19167839.0T patent/LT3527199T/lt unknown
- 2013-01-23 HU HUE18181331A patent/HUE061566T2/hu unknown
- 2013-01-23 PL PL19167839.0T patent/PL3527199T3/pl unknown
- 2013-01-23 PL PL13704372T patent/PL2806855T3/pl unknown
- 2013-01-23 DK DK19167835.8T patent/DK3527198T3/da active
- 2013-01-23 RS RS20221033A patent/RS63759B1/sr unknown
- 2013-01-23 GE GEAP201313532A patent/GEP201706767B/en unknown
- 2013-01-23 ES ES19167775T patent/ES2928688T3/es active Active
- 2013-01-23 JP JP2014553692A patent/JP6104282B2/ja active Active
- 2013-01-23 EA EA201690187A patent/EA031566B1/ru unknown
- 2013-01-23 CA CA2862548A patent/CA2862548C/en active Active
- 2013-01-23 RS RS20220971A patent/RS63706B1/sr unknown
- 2013-01-23 DK DK19167829.1T patent/DK3527197T3/da active
- 2013-01-23 PL PL19167835.8T patent/PL3527198T3/pl unknown
- 2013-01-23 PT PT191678291T patent/PT3527197T/pt unknown
- 2013-01-23 RS RS20230066A patent/RS63952B1/sr unknown
- 2013-01-23 RS RS20181038A patent/RS57637B1/sr unknown
- 2013-01-23 LT LTEP19167775.6T patent/LT3527196T/lt unknown
- 2013-01-23 UA UAA201408448A patent/UA115543C2/uk unknown
- 2013-01-23 MX MX2016001311A patent/MX368199B/es unknown
- 2013-01-23 EP EP19167829.1A patent/EP3527197B1/en active Active
- 2013-01-23 FI FIEP19167835.8T patent/FI3527198T3/fi active
- 2013-01-23 PL PL18181331.2T patent/PL3412277T3/pl unknown
- 2013-01-23 MX MX2014008631A patent/MX355729B/es active IP Right Grant
- 2013-01-23 PT PT191678358T patent/PT3527198T/pt unknown
- 2013-01-23 HU HUE19167775A patent/HUE060402T2/hu unknown
- 2013-01-23 HU HUE19167835A patent/HUE069624T2/hu unknown
- 2013-01-23 KR KR1020147019763A patent/KR101560288B1/ko active Active
- 2013-01-23 PE PE2014001166A patent/PE20141703A1/es active IP Right Grant
- 2013-01-23 HR HRP20241638TT patent/HRP20241638T1/hr unknown
- 2013-01-23 ES ES13704372.5T patent/ES2683254T3/es active Active
- 2013-01-23 HR HRP20221431TT patent/HRP20221431T1/hr unknown
- 2013-01-23 LT LTEP19167829.1T patent/LT3527197T/lt unknown
- 2013-01-23 EP EP15202117.6A patent/EP3020394A1/en not_active Withdrawn
- 2013-01-23 NZ NZ627837A patent/NZ627837A/en unknown
- 2013-01-23 LT LTEP13704372.5T patent/LT2806855T/lt unknown
- 2013-01-23 EP EP19167835.8A patent/EP3527198B1/en active Active
- 2013-01-23 KR KR1020157019169A patent/KR101786586B1/ko active Active
- 2013-01-23 PT PT181813312T patent/PT3412277T/pt unknown
- 2013-01-23 DK DK13704372.5T patent/DK2806855T3/en active
- 2013-01-23 ES ES18181331T patent/ES2938466T3/es active Active
- 2013-01-23 PL PL19167829.1T patent/PL3527197T3/pl unknown
- 2013-01-23 DK DK19167775.6T patent/DK3527196T3/da active
- 2013-01-23 FI FIEP18181331.2T patent/FI3412277T3/fi active
- 2013-01-24 AR ARP130100225A patent/AR089805A1/es not_active Application Discontinuation
- 2013-01-24 US US13/748,882 patent/US8778402B2/en active Active
- 2013-01-24 TW TW102102606A patent/TWI559940B/zh active
-
2014
- 2014-07-07 PH PH12014501565A patent/PH12014501565B1/en unknown
- 2014-07-11 MA MA37200A patent/MA35859B1/fr unknown
- 2014-07-24 TN TNP2014000322A patent/TN2014000322A1/fr unknown
- 2014-07-24 CL CL2014001966A patent/CL2014001966A1/es unknown
- 2014-07-24 CO CO14161092A patent/CO7010836A2/es unknown
- 2014-07-24 ZA ZA2014/05464A patent/ZA201405464B/en unknown
- 2014-07-24 IL IL233784A patent/IL233784A0/en active IP Right Grant
-
2018
- 2018-06-22 US US16/015,666 patent/US10946029B2/en active Active
- 2018-09-11 CY CY181100948T patent/CY1120684T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI559940B (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| IL243507A0 (en) | A dry powder formulation containing an anticholinergic agent, a steroid and an adrenergic agent for inhalation administration | |
| HUE042757T2 (hu) | Szállító szert tartalmazó készítmények és elõállításuk | |
| ZA201308905B (en) | Nasal pharmaceutical formulation comprising fluticasone | |
| IL227651A (en) | Topical pharmacological formulations containing 220b | |
| PT3409270T (pt) | Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação |